Monday, November 27, 2006 7:30:00 AM PDT | VentureDeal Staff
MALVERN, PA - Solstice Neurosciences announced the closing of a new round of financing totaling $85 million of both equity and debt. Highland Capital Management led the Series B round, with participation from earlier investors Thomas, McNerney & Partners, Investor Growth Capital Inc., Morgan Stanley Venture Partners, and Oxford Bioscience Partners. The proceeds will allow the company to pursue continued development for treatments for movement disorders and cervical dystonia.
Email Page | Print Page
Want unlimited access to the complete database with thousands of technology companies, VCs and transactions for only $25 per month?
Start your Free 14 Day Trial now – no obligation or credit card required.
